Role of aripiprazole in treating mood disorders

References

• Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev. Neurother.5(3), 297–307 (2005).
   PubMedGoogle Scholar
• Davies MA, Sheffler DJ 3rd, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a unique robust pharmacology. CNS Drug Rev.10(4), 317–336 (2004).
   PubMedGoogle Scholar
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry156, 286–293 (1999).
   PubMed Web of Science ®Google Scholar
• Kapur SJ, Zipursky R, Jones C, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double blind PET study of first-episode schizophrenia. Am. J. Psychiatry157, 514–520 (2000).
   PubMed Web of Science ®Google Scholar
• Hirose T, Uwahodo Y, Yamada S et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J. Psychopharmacol.18(3), 375–383 (2004).
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Perry CM. Aripripazole in acute mania associated with bipolar I disorder. CNS Drugs18(6), 367–376 (2004).
   PubMed Web of Science ®Google Scholar
• Grunder G, Carlson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch. Gen. Psychiatry60, 74–77 (2003).
   Google Scholar
• Reckless G, Natesan S, Parker J et al. Dissociation between blockade and functional antagonism of D2 receptors – comparing aripiprazole to other typical and atypical antipsychotics in animal models. Schizophrenia Bull.31(2), 309 (2005).
   Google Scholar
• Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J. Clin. Pharmacol.45(1), 89–93 (2005).
   PubMed Web of Science ®Google Scholar
• Vieta E. Atypical antipsychotics in mood disorders. Curr. Opin. Psychiatry16, 23–27 (2003).
   Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry60(11), 1079–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, McFadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry.162(7), 1351–1360 (2005).
   PubMed Web of Science ®Google Scholar
• Thase M, McCoy R, Chang W, MacFadden W. Efficacy of quetiapine monotherapy in bipolar depression: a confirmatory, placebo-controlled study (the BOLDER II study). Presented at: The 159th APA Annual Meeting, Toronto, Canada, May 20–25 (2006).
   Google Scholar
• Keck PE Jr, Marcus R, Tourkodimitris S et al. Placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry160(9), 1651–1658 (2003).
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.J. Psychopharmacol.20(4), 536–546 (2006).
   PubMed Web of Science ®Google Scholar
• Vieta E, Bourin M, Sanchez R et al. Effectiveness of aripripazole vs haloperidol in acute bipolar mania: double-blind, randomized, comparative 12-week trial. Br. J. Psychiatry187, 235–242 (2005).
   PubMed Web of Science ®Google Scholar
• Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord.7(Suppl. 4), 21–33 (2005).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Calabrese JR, Mc Quade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry67(4), 626–637 (2006).
   PubMed Web of Science ®Google Scholar
• Vieta E. Maintenance therapy for bipolar disorder: current and future management options. Expert Rev. Neurother.4(Suppl. 2), 35–42 (2004).
   PubMedGoogle Scholar
• Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) (Epub ahead of print).
   Google Scholar
• Yatham LN, Goldstein JM, Vieta E et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry66(Suppl. 5), 40–48 (2005).
   PubMed Web of Science ®Google Scholar
• Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann. Clin. Psychiatry18(3), 169–172 (2006).
   PubMedGoogle Scholar
• Vieta E. Bipolar mixed states and their treatment. Expert Rev. Neurother.5, 63–68 (2005).
   PubMedGoogle Scholar
• Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J. Clin. Psychiatry66, 1216–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J. Clin. Psychiatry66, 1326–1330 (2005).
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry16, 189–194 (2004).
   PubMedGoogle Scholar
• Biederman J, McDonnell MA, Wozniack J et al. Aripripazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr.10(2), 141–148 (2005).
   PubMed Web of Science ®Google Scholar
• Barzman DH, DelBello MP, Kowatch RA et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. CNJ Child Adolesc. Psychopharmacol.14(4), 593–600 (2004).
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry60, 681–690 (2003).
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry63, 763–771 (2002).
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol.6(4), 325–337 (2003).
   PubMed Web of Science ®Google Scholar
• Casey D, L’Italien GJ, Cislo P. Comparative one year incidence/worsening of metabolic syndrome among patients treated with olanzapine vs aripiprazole. Schizophrenia Bull.31(2) 343–350 (2005).
   Google Scholar
• McQuade RD, Stock E, Marcus R et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry65(Suppl. 18), 47–56 (2004).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care27, 596–601 (2004).
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs18(13), 877–893 (2004).
   PubMed Web of Science ®Google Scholar
• Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int. Clin. Psychopharmacol.19(6), 351–353 (2004).
   PubMed Web of Science ®Google Scholar